Economics & Value

New Value Model Incorporates Long-Term Adverse Effects of Cancer Drugs

Chase Doyle

February 2017, Vol 8, No 1 - Value-Based Care

A new economic model suggests that overall survival and drug toxicity profiles are insufficient for assessing the value of a drug. According to a study that incorporated late adverse events in advanced Hodgkin lymphoma, a more comprehensive benefit-to-risk ratio of a drug requires an understanding of its long-term health implications, said Ohad Oren, MD, Pennsylvania Hospital, University of Pennsylvania, Philadelphia, at the 2016 American Society of Hematology meeting. [ Read More ]

Patients with Cancer Eager to Discuss Costs of Care with Their Oncologists

Laura Morgan

September 2015, Vol 6, No 8 - Economics of Cancer Care

Gone are the days when patients with cancer were, for the most part, protected from healthcare costs by their medical insurance. According to a recent study sponsored by the National Comprehensive Cancer Network and conducted by Ronan J. Kelly, MD, MBA, MBBCh, Assistant Professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, and colleagues, with high deductibles, escalating copayments, and cost-sharing requirements becoming the status quo, patients with cancer are now, more than ever, feeling the effects of financial toxicity, particularly young patients who are especially susceptible to filing for medical bankruptcy (Kelly RJ, et al. J Oncol Pract. 2015;11:308-312). [ Read More ]

Assessing the Cost-Effectiveness of Necitumumab in Squamous-Cell Lung Cancer

Dana Taylor

August 2015, Vol 6, No 7 - Economics of Cancer Care

Chicago, IL—An economic analysis presented by Daniel Goldstein, MD, of Emory University, Atlanta, GA, at the 2015 American Society of Clinical Oncology meeting, was conducted to see at what price will necitum­umab (which is currently being reviewed by the FDA for use in metastatic squamous-cell lung cancer) be cost-­effective. According to this analysis, necitumumab will have to be priced at less than $1300 per cycle to be cost-­effective based on the accepted willing­ness-to-­pay threshold of $150,000. [ Read More ]

The New PC-SAF Instrument: A Patient-Reported Outcome Tool for Identifying the Symptoms of Pancreatic Cancer

Laura Morgan

June 2015, Vol 6, No 5 - Economics of Cancer Care

Philadelphia, PA—The prognosis for patients with pancreatic cancer, the leading cause of cancer-related deaths in the United States, remains poor. The diagnosis of pancreatic cancer is often delayed to a late stage, which affects impact. Improving the understanding of the early signs and symptoms of this cancer may improve outcomes. [ Read More ]

Increasing Use of Value Analysis Committees in US Hospitals: Implications for Healthcare Providers and Manufacturers

Laura Morgan

June 2015, Vol 6, No 5 - Economics of Cancer Care

Philadelphia, PA—The growing focus on identifying and preventing overpayments and reducing waste in the healthcare system has prompted hospitals to adopt value analysis committees to curb unnecessary medical supply spending. In 2012, as many as 64% of US hospitals were using a value analysis committee to evaluate new devices and new supplies used in their institutions. [ Read More ]